Glioma　is　the　most　common　primary　intracranial　tumor,　which　is　formed　by　the　malignant　transformation　of　glial　cells　in　the　brain　and　spinal　cord.　It　has　the　characteristics　of　high　incidence,　high　recurrence　rate,　high　mortality　and　low　cure　rate.　The　treatments　for　glioma　include　surgical　removal,　chemotherapy　and　radiotherapy.　Due　to　the　obstruction　of　the　biological　barrier　of　brain　tissue,　it　is　difficult　to　achieve　the　desired　therapeutic　effects.　To　address　the　limitations　imposed　by　the　brain＇s　natural　barriers　and　enhance　the　treatment　efficacy,　researchers　have　effectively　used　brain-targeted　drug　delivery　systems　(DDSs)　in　glioma　therapy.　Polyamidoamine　(PAMAM)　dendrimers,　as　branched　macromolecular　architectures,　represent　promising　candidates　for　studies　in　glioma　therapy.　This　review　focuses　on　PAMAM-based　DDSs　in　the　treatment　of　glioma,　highlighting　their　physicochemical　characteristics,　structural　properties　as　well　as　an　overview　of　the　toxicity　and　safety　profiles.